CPhI Pharma R&D and Collaboration Strategy - China Conference (CPhI China Conferenc)
|Event Date/Time: Jun 21, 2011||End Date/Time: Jun 22, 2011|
|Registration Date: Jun 20, 2011|
|Early Registration Date: Apr 22, 2011|
Start from Europe, CPhI Conferences organizes a worldwide series of pharmaceutical events across four key areas. In close conjunction with CPhI Worldwide, CPhI Conferences deliver the latest market trends, critical case study insights and exceptional networking opportunities through a programme of high-level conferences, subjects of which focus on New Drug Discovery, Biopharm, Biosimilars, CRO/CMO, API Sourcing, Generics and Export Strategies, etc.
China, with a GDP of more than $8,000 billion, is poised to become the worldâ€™s third-largest pharmaceutical market in 2011 - up from number eight in 2006. Most of the growth in China will continue to come from branded generic products manufactured and marketed by established domestic companies, although demand for innovative products from multinational companies is rising in the countryâ€™s leading urban centers. Besides, in 2010, the China government has allocated around 30 billion RMB to support the R&D of new drug and biological products. For local China pharma companies, it is crucial to seize the opportunities of new drugs discovery and patents expiration, to empower pharma R&D efficiency and ensure high product quality, even explore global market in fast steps. And for global big pharma companies, China, such an emerging market, to drive new opportunities with cost-effective R&D and outsourcing strategies is rather important. It is obvious that the early movers will get advantages.
So the first CPhI China Conference, â€œCPhI Pharma R&D and Collaboration Strategy - China Conferenceâ€, will bring together both Chinese and global pharma companiesâ€™ views in China market. 30 eminent speakers from global and Chinese big pharmaceutical companies and research institutes, like FDA, Novartis, USP-China, Roche R&D Center, GSK China/HK, AstraZeneca Innovation Centre China, Sanofi-Aventis, REVA PHARMA, Dr.Reddy's & Shanghai Pharma, etc., will share great experiences and new research findings. Further in-depth case studies will cover both pharma R&D and business development strategies by an outstanding panel of Chinese, Indian and international speakers from industry leaders. More hot topics include,
ï¬ Understanding and Overcoming the Challenges in Registration of Bio-pharmaceutical in China
ï¬ Discovering Monoclonal Antibodies through Successfully Target Validation to Deliver Commercially Viable Biologics to the Market
ï¬ Brand Patent vs. Patent Expirationâ€”Gaining Insider Perspective on Global Big Pharmaceutical Companiesâ€™ Strategy in Value Added Generic â€œBrandingâ€
ï¬ Specifying Key Points of Successfully Entering and Occupying Large Market Share in Generic Industry
ï¬ Alliances, Mergers and Acquisitionsâ€”Changing the Generic Landscape Globally
ï¬ Protecting Intellectual Property and Confidential Technology While Executing CMO in China
Taking place in concurrence with CPhI & ICSE China Exhibition, There will be a one-stop platform to ideally optimize the audienceâ€™s timetable & focus during the events. 7 individually bookeable 3-hour modules can be easily selected. To learn more about the conference, please go to www.cphichina-conference.com .